Merck to report Q1 results with focus on Keytruda Qlex sales and potential FDA approval.

Merck & Co. is set to release its first-quarter financial results at the end of April, with expectations of strong sales from its cancer drug Keytruda and Winrevair. A key highlight will be the performance of Keytruda Qlex, designed to counter biosimilar competition expected from 2028. Investors are also watching the potential FDA approval of Keytruda Qlex combined with Padcev for bladder cancer treatment, expected on August 17. These developments contribute to an attractive risk/reward profile for Merck despite current geopolitical uncertainties.